IDiyas

For the Inventor, By the Inventor

Tinton Falls, NJ, United States of America

Ralph A Rivero

USPTO Granted Patents = 19

Average Co-Inventor Count = 4.9

ph-index = 12

Forward Citations = 404(Granted Patents)


Location History:

  • Eatontown, NJ (US) (1993)
  • Tinton Falls, NJ (US) (1993 - 1997)
  • North Wales, PA (US) (1998)

Company Filing History:

goldMedal19 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1993-1998

Loading Chart...
19 patents (USPTO):Explore Patents
1. 5767310 - Phenoxyphenylacetic acid derivatives (1998-06-16),
2. 5668176 - Phenoxyphenylacetic acid derivatives (1997-09-16),
3. 5565485 - Biphenyl compounds useful or endothelin antagonists (1996-10-15),
4. 5554625 - Substituted biphenylmethylimidazopyridines (1996-09-10),
5. 5492917 - Endothelin antagonists incorporating a cyclobutane (1996-02-20),
6. 5449682 - Angiotensin II antagonists incorporating a substituted benzyl element (1995-09-12),
7. 5444067 - Pharmaceutical treatment methods using angiotensin II receptor agonists (1995-08-22),
8. 5412097 - Heterocyclic compounds bearing acidic functional groups as angiotensin (1995-05-02),
9. 5312820 - Substituted carbamoyl and oxycarbonyl derivatives of biphenylmethylamines (1994-05-17),
10. 5264439 - Quinazolinone, triazolinone and pyrimidinone angiotensin II antagonists (1993-11-23),
11. 5252574 - Angiotensin II antagonists incorporating a substituted thiophene or furan (1993-10-12),
12. 5240938 - Angiotensin II antagonists incorporating a substituted pyridoimidazolyl (1993-08-31),
13. 5223499 - 6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists (1993-06-29),
14. 5198438 - Angiotensin II antagonists incorporating a substituted thiophene or furan (1993-03-30),
15. 5194605 - Cyclic renin inhibitors containing 2-substituted (1993-03-16),

Title: Ralph A. Rivero: Innovator in Cardiovascular Therapeutics

Introduction: Ralph A. Rivero is a notable inventor based in Tinton Falls, NJ, with an impressive portfolio comprising 19 patents. His work primarily focuses on innovations that address critical health issues, particularly in the field of cardiovascular disorders.

Latest Patents: Among his most recent contributions to the field are the patents related to phenoxyphenylacetic acid derivatives. These compounds exhibit endothelin antagonist activity, making them instrumental in treating various cardiovascular conditions such as hypertension, postischemic renal failure, vasospasm, cerebral and cardiac ischemia, myocardial infarction, endotoxic shock, benign prostatic hyperplasia, and inflammatory diseases, including Raynaud's disease and asthma.

Career Highlights: Ralph A. Rivero has made significant strides in pharmaceutical research and development while working for Merck & Company, Inc. His dedication to innovating therapeutic solutions has positioned him as a key contributor in this competitive industry. His consistent efforts in research have resulted in an array of patents that benefit numerous patients suffering from cardiovascular complications.

Collaborations: Throughout his career, Rivero has collaborated with esteemed colleagues, including William J. Greenlee and Thomas F. Walsh. These partnerships have been crucial in advancing his research and in the successful development of new therapeutic agents.

Conclusion: Ralph A. Rivero's innovative work and dedication to addressing cardiovascular disorders through his patents exemplify the important role that inventors play in advancing medical science. His contributions not only showcase his expertise but also demonstrate a commitment to enhancing patient care through groundbreaking research.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…